SCHEMBL19686702

SCHEMBL19686702

Cc1ccn(-c2nc(NC3CCC(O)CC3)cc(N3CCOCC3)n2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.51
CCNT1 O60563 1/20 0.46
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
KMT2A Q03164 5/20 0.42
KDM4E B2RXH2 8/20 0.41
MEN1 O00255 4/20 0.41
GAA P10253 4/20 0.41
ALDH1A1 P00352 3/20 0.41
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 6/20 0.41
LMNA P02545 5/20 0.41
HPGD P15428 1/20 0.41
PDE10A Q9Y233 1/20 0.39
POLB P06746 3/20 0.39
NSD2 O96028 1/20 0.39
MAPK1 P28482 1/20 0.39
MPI P34949 1/20 0.39
SENP7 Q9BQF6 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19686381 0.91 ADORA2A (0.43) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL19686709 0.90 ADORA2A (0.42) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL21578586 0.90 HRH4 (0.44) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL19686704 0.88 ADORA2A (0.41) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL19686717 0.88 ADORA2A (0.41) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL19686705 0.88 KDM4E (0.41) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL19686708 0.88 ADORA2A (0.46) PIK3CAADORA2AADORA1KMT2AKDM4E
SCHEMBL19686716 0.88 ADORA2A (0.46) PIK3CAADORA2AADORA1KMT2AKDM4E
Rimtuzalcap SCHEMBL19686931 0.86 IDH1 (0.43) PIK3CAADORA2AADORA1KMT2AKDM4E
Rimtuzalcap SCHEMBL29920754 0.86 IDH1 (0.43) PIK3CAADORA2AADORA1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 PIK3CA 1182/4885CCNT1 4771/4885ADORA2A 1711/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 PIK3CA 1182/4885CCNT1 4771/4885ADORA2A 1711/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 PIK3CA 1182/4885CCNT1 4771/4885ADORA2A 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.